Copaxone sales fall; Mylan to acquire Swedish drugmaker; health insurers report financial losses from ACA plans
She is the first chief marketing officer for Shatterproof.
The FDA is set to announce its decision on the drug in April.
Lions Health, launched in 2014, generated $1.9 million in revenue last year.
SEC is investigating Salix Pharmaceuticals; FDA adcomm recommends approval of Remicade biosimilar; Medicare considers payment changes
The campaign targets 86 million Americans, 90% of whom aren't aware they have the condition.
The FDA to review biosimilar Remicade; lawmaker looks at panelists' ties to painkiller manufacturers; Novartis signs risk-sharing contracts for Entresto
The newly launched tools aim to reduce the time and costs of marketing new drugs by "debugging" the lab environment.
Finicky formulary committees and rising consumer cost consciousness add up to a new market dynamic for health brands. A new survey helps break it down.
It's the industry's biggest turnout in the Super Bowl in three years.
PhRMA and BIO ramp up ad spend for presidential election year; Super Bowl Sunday features three pharma ads; Pfizer solidifies leadership team
Johnson & Johnson collaborates with biotech on diabetes stem-cell treatment; the FDA warms up to Remicade biosimilar; Woodcock warns about biosimilar backlog
The Ketchum veteran joined the nonprofit healthcare system in mid-2014.
A House lawmaker called pricing strategies used by Turing and Valeant "repulsive."
Burcin's charge is to keep momentum going at the indie agency, known for placing ice-cream carts outside of rival agencies and other recruiting tactics.
Valeant to push for changes to financial-assistance rules; House to hold hearing on drug-pricing practices; FDA committee says Lundbeck can add information to leaflet
After Bill McEllen's departure, the company promoted Mark Willmann to lead the agency.
FitzPatrick is departing the company as it evaluates its 150 agency partnerships.
Seven potential blockbusters set to launch in 2016; Amarin case may lead to 'misleading' marketing; Valeant, Turing raised prices to meet preset targets
Click for an infographic to learn more about orphan drugs, rare diseases and the top-selling drugs in the category.
Gleevec generics hit shelves; four OxyContin patents are invalidated; Sanofi axes 600 positions
Plus other industry hires and changes
The awards have four new categories: Best Use of Relationship Marketing, Best Use of Data/Analytics, Best Film or Video, and Most Daring Campaign.
AbbVie cuts 2016 sales estimate for Viekira Pak; Abbott to acquire Alere for $5.8 billion; Express Scripts to stop covering Valeant's Glumetza
The pharmaceutical company reported a 2% revenue increase in 2015, and diabetes medication is a key contributor.
The Silicon Valley gadget guru who helped define the beyond-the-pill era will talk about embedding nontraditional capabilities into biopharma business models.
The drugmaker's CEO said the campaign helps dispel pessimism created from a history of cancer drugs that lack "significant value."
FDA approves Merck's HCV doublet regimen; Gilead CEO steps down; Clinton takes aim at Valeant price hikes
In many cases, the drug required physicians to request prior authorization.
Sales of cystic-fibrosis drug Orkambi higher than expected; new sensor tracks sweat; J&J develops clinical trial to find new way to treat depression
Biogen execs said a recently launched DTC campaign for Tecfidera is showing positive early signs.
Former Biosector 2 US MD Jeanine O'Kane was named inVentiv Health PR Group's US MD.
The FDA plans to release new guidance on advertising in 2016; Trump supports Medicare price negotiations; Novartis CEO: golden days of drug pricing are over
Faced with slowing sales, the company is in the early stages of developing value-added services that support better patient outcomes.
Following November pitch, WPP agency will handle digital strategy, creative and social in region.
The FDA accepts bid for new label for Jardiance; Markey puts on a hold on Califf's FDA nomination; GSK is studying the Zika virus
Valeant CEO is recovering; three drugmakers partner for early-stage cancer research
Michel Murino, former CEO of southern Europe and France, will now head the company's regional operations in Europe.
NICE recommends Opdivo for skin cancer; Sanofi layoffs could be looming; Senators ask for feedback on Sovaldi investigation
The Office of Prescription Drug Promotion said Hospira, now a Pfizer subsidiary, omitted information and misbranded the drug.
"A global launch of a type-2 diabetes drug. It was a four-year trail of cheers and tears."
The agency named a new chief strategist and creative director along with new leads for its Minnesota, Chicago and New York healthcare practices.
GSK CEO says consumer health business could be its own entity; regulatory setbacks cloud future of DMD treatments; OPDP slams YouTube video
Part of drugmakers' sales growth stems from price increases; AbbVie's Venetoclax gets second Breakthrough designation; two states in India stop Avastin sales
They will attempt to develop a new industry standard for digital advertising viewability, a much debated topic that has vexed the broader advertising industry.
Pinnacle Health Communications and Franklyn Healthcom merge to offer "more complete" customer-centric solutions.
Government pressure can influence drug-pricing decisions; Samsung's biosimilar version of Enbrel is approved in Europe; J&J to cut jobs in medical-devices business
Part of LinkedIn's appeal lies in the high level of engagement of its members and the potential for precise targeting of content and talent searches.
The FDA declines to approve two drugs for Duchenne muscular dystrophy; government watchdog questions FDA's post-market drug tracking; WebMD denies acquisition talks
Summit Partners' investment in the health information site expected to aid the company's efforts to compete with sites like WebMD
Drugmakers seeking to develop "beyond-the-pill" digital initiatives have to be willing to engage patients in new ways, McKinsey & Company report finds.
Valeant is "uncertain" when CEO will return; Bayer hires Razorfish and iCrossing for digital; more drugmakers that sell hemophilia drugs are hiring patients
Biden to lead "moonshot" to cure cancer; Pfizer/Allergan merger to create "best pipeline in the industry," CEO says; AMA invests in health tech startup
The healthcare agency debuts with Swedish-based pharma company Orexo as its first client.
Two senators, including presidential candidate Bernie Sanders, threatened to hold up his nomination.
The FDA in November approved three new drugs that treat the rare blood cancer.
HCPs sound off on CMS opioid proposal; Senate committee to decide if Califf gets FDA commissioner nod; Celgene names new CEO
Mazzola says healthcare advertising is having a watershed moment.
Shire buys Baxalta, creates world's largest rare-disease drugmaker; drug prices continue to climb; immunotherapy coalition is formed
The digital health sector brought in an estimated $6 billion in funding in 2015.
Damian Braga, who held the role previously, retired after 27 years working for the drugmaker
GSK will stop using outside doctors to promote its drugs; Roche will file its immuno-oncology drug for approval; Mylan inks deal to develop six biosimilars
Fitbit faces allegations of inaccurate heart monitoring; Viiv Healthcare to collaborate with Janssen; Guardant Health raises funding for its cancer blood tests
Nashville-based ReviveHealth posted $8.7 million in revenue in 2014.
Millennials at pharma agencies are driven and tech-savvy but also pay too much attention to promotion and the shape of their careers, say agency leaders.
The drugmaker led a Series C fundraising round totaling $175 million. The funding will be used to accelerate clinical trials.
Lilly's Jardiance starting to gain market share; Merck "raring" to make acquisitions; Sanofi said it will stop marketing Afrezza
Sanofi spent $3.75 million on advertising for Afrezza in the third quarter of 2015 yet the therapy only brought in about $2 million in revenue.
The American Association of Advertising Agencies said stopping calls for a ban on DTC is a top agenda item for the trade group in 2016.
Gilead's hep-C combo gets Breakthrough designation; Baxalta licences experimental cancer drugs; Novartis agrees to settle class-action lawsuit
As students, about 27% of MM&M's healthcare transformers received degrees in subjects that did not include health, business or technology.
A Q&A with Sandra Carey, president of the McCann Pharmacy Initiative, on the move to push pharmacy to the forefront.
The FDA approved 45 new drugs in 2015; Baxalta signs immuno-oncology deal; pharma M&A activity may slow this year
FCB Health opted to merge the two agencies and rebrand their US shops, which together plan to fill 40 open positions in 2016.
Generic Nexium will be blue; researcher says scientific papers should be anonymous; patients with health insurance still struggle to cover the costs of drugs
The main accreditation body for CME activities traded barbs with an academic critic over courses designed to enlighten doctors about hypoactive sexual desire disorder.
Twenty percent of publicly funded cancer clinical trials don't enroll enough patients; KaloBios files for bankruptcy; a new MS campaign in Australia uses bicycles
The healthcare marketing and communications network aims to bolster its offering for the drug industry's growing demand for KOL engagement.
Rick Berke, executive editor of Stat, talks about the title's strategy to make health, medicine and life sciences content compelling and deliver this news to a general audience.
The new chief digital officer at Makovsky, Justin Chase, says the client-customer relationship in healthcare has fundamentally changed.
Generic-drug approval backlog criticized; KaloBios board members step down; Sovaldi costs as little as $4 in India
Valeant CEO takes medical leave; average asthma rates for US children trends downward; drugmakers paid $7 billion for coupons and co-pay cards in 2015
Campaigns around opioid abuse, lung cancer drugs and women's health took the spotlight in 2015.
Clinton calls for Alzheimer's funding; an FDA approval of an older drug may mean higher prices; the FDA approves AstraZeneca's gout drug
Drug pricing is easily the biggest controversy but pharma faced other issues, too, like the AMA's call to ban DTC advertising.
Private equity firm TPG Growth invested in the healthcare services company, which plans to use the funds to expand its capabilities and reach.
The firm began working with the pharma company before outrage over its drug pricing but has more recently supported the client after former CEO Martin Shkreli was arrested.
Valeant says it lost few reps despite business scrutiny; Novartis CEO says drugmakers must share benefits of new medicines with other healthcare stakeholders; Bloomberg analysis finds US pays more for branded drugs after discounts
Mergers, acquisitions and reorganizations among pharma agencies piqued your interest in 2015.
Shkreli resigns from Turing; Keytruda approved as first-line melanoma treatment; drugmakers seek to fend off California pricing ballot initiative
An award-winning campaign about talking fish; the OTC switch for GlaxoSmithKline's Flonase; a direct-to-consumer push for Afrezza, Sanofi's and MannKind's inhaled insulin
The note is exceptional not merely for its passion—Bernbach admits to being "damned worried" about the agency's future—but for its historical resonance.
GlaxoSmithKline buys Bristol-Myers Squibb's research assets; Gilead Sciences makes large stake in experimental rheumatoid arthritis drug; Avandia's REMS program ends
Eli Lilly and Boehringer Ingelheim received approval to begin selling their Lantus knock-off drug after settling a patent lawsuit with Sanofi in September.
The deal not only creates the world's largest drugmaker but also one of the world's largest advertisers.
The FDA approves Lilly's Lantus follow-on biologic; AstraZeneca buys majority stake in Acerta Pharma; Shkreli arrested on securities fraud charges
Britain says Bristol-Myers Squibb's Opdivo is too expensive; Calpers reports 32% boost in specialty drug spending; NIH is funding fewer clinical trials
The FDA withdrew a 2014 warning letter related to Pacira Pharmaceuticals' marketing of its painkiller Exparel as part of a settlement reached by both parties this week.
IPG's McCann Health announces branding and operational changes aimed at integrating its US and Canadian shops.
Valeant agrees to cut prices in deal with Walgreens; FDA committee votes against Merck's Vytorin claims; Pacira settles off-label marketing case with the FDA